#weightlossdrug
weightlossdrug
15 views
2 Discussing
Hot
Latest
$LLY NEXT WEIGHT-LOSS BLOCKBUSTER – RETATRUTIDE FUELS A BULLISH PARADIGM SHIFT 🟢💊
📌 While traders chase crypto pumps, smart money is quietly accumulating $LLY ahead of a potential $3.8B revenue stream from Retatrutide—a triple-hormone GLP-1/GIP/glucagon therapy that crushed phase 3 trials with 22.6% weight loss in obese heart patients. 📊 The 2% price reaction is just the surface; underneath, 20 out of 22 analysts rate it a Buy with a $1,294 average target, implying 17% upside from current levels.
💡 This is the kind of asymmetric risk-reward that institutional portfolios are built around. The delayed FDA filing (Q1 2027) only creates a deeper discount for patient capital. 💬 Do you have $LLY on your radar, or are you waiting for the clinical data to fully hit the mainstream? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #Biotech #WeightLossDrug #Pharma #Bullish
💎 🚀
📌 While traders chase crypto pumps, smart money is quietly accumulating $LLY ahead of a potential $3.8B revenue stream from Retatrutide—a triple-hormone GLP-1/GIP/glucagon therapy that crushed phase 3 trials with 22.6% weight loss in obese heart patients. 📊 The 2% price reaction is just the surface; underneath, 20 out of 22 analysts rate it a Buy with a $1,294 average target, implying 17% upside from current levels.
💡 This is the kind of asymmetric risk-reward that institutional portfolios are built around. The delayed FDA filing (Q1 2027) only creates a deeper discount for patient capital. 💬 Do you have $LLY on your radar, or are you waiting for the clinical data to fully hit the mainstream? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #Biotech #WeightLossDrug #Pharma #Bullish
💎 🚀
Log in to explore more content